Healthcare Business

Pot Grower Aphria Gets C$100 Million Strategic Investment

Ontario-based Aphria Inc. (NYSE: APHA) announced Friday that the company has accepted a strategic investment from an unnamed institutional investor of C$100 million (US$76.14 million) to acquire 14.04 million units. ...
Read Full Story »

How Earnings Will Dictate Biotech Sector’s Fate in 2020

So far in 2020, the overall sentiment in the market still seems good following a strong finish to 2019. This is especially true among biotechnology stocks. The biotechs experienced large ...
Read Full Story »

This Biotech Could Make a Big Splash With the Coronavirus Scare

The newest coronavirus out of China has resulted in a rising interest in biotechs that may be able to produce a vaccine or treatment with a short turnaround. We’ve seen ...
Read Full Story »

Are Investors Overreacting to This Achromatopsia Study?

Applied Genetic Technologies Corp. (NASDAQ: AGTC) shares were crushed early Thursday after the firm reported interim data from its midstage trial in patients with achromatopsia. While the company says that ...
Read Full Story »

Why This Cardiovascular Disease Study Could Be Huge

Akcea Therapeutics Inc. (NASDAQ: AKCA) and Ionis Pharmaceuticals Inc. (NASDAQ: IONS) each made handy gains on Wednesday after they reported midstage results for their cardiovascular disease study. Specifically, the results ...
Read Full Story »

Some Great News for Potential Alzheimer’s Treatment

It may be unusual to see a stock rise close to 100% without a corporate buyout, but in biotech and emerging pharmaceutical companies gains of that size can occur simply ...
Read Full Story »

Why Johnson & Johnson Stock Is Not Reacting More Positively to Earnings

Johnson & Johnson (NYSE: JNJ) reported fourth-quarter 2019 results before markets opened Wednesday. The health care giant reported quarterly adjusted diluted earnings per share (EPS) of $1.88 on revenue of ...
Read Full Story »

China’s Coronavirus Could Prompt Buying Frenzy in These Biotech Stocks

China is facing an outbreak of the coronavirus, which may have spread to a few other countries in East Asia. Although less than 300 infections have been reported, there are ...
Read Full Story »

FDA Fast Track on Lung Cancer Treatment Brings Exponential Gains for This Microcap Stock

When companies see their shares rise by 100% or more in a single day, it's usually because of a buyout or an extremely positive change in a company's future prospects. ...
Read Full Story »

Winning Ideas in Biotech/Pharma After JPMorgan Healthcare Conference

For health care investors, 2020 looks like a potentially good year after an especially fruitful JPMorgan Healthcare Conference this past week. In fact, brokerage firm Janney spent last week visiting ...
Read Full Story »

This Week’s Biggest Biotech Movers

As the biotechnology group is pushing near all-time highs, this past week played host to a huge number of biotech movers. 24/7 Wall St. has picked a few of these ...
Read Full Story »

What’s Next for Durect After FDA Posimir Vote

Durect Corp. (NASDAQ: DRRX) shares dropped early on Friday after the U.S. Food and Drug Administration Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) announced its vote on Posimir, the ...
Read Full Story »

Are Neon Therapeutics’ Shareholders Getting Enough in the Buyout?

Neon Therapeutics Inc. (NASDAQ: NTGN) shares shot up on Thursday after the firm announced that it will be acquired by BioNTech SE (NASDAQ: BNTX). The question is: Are Neon Therapeutics ...
Read Full Story »

Why This Opioid Painkiller Is Killing Nektar Therapeutics Stock

Nektar Therapeutics (NASDAQ: NKTR) shares were crushed on Wednesday after the U.S. Food and Drug Administration (FDA) Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management ...
Read Full Story »

Does FDA Decision Mean a Bright Future for This Flu Vaccine?

Novavax Inc. (NASDAQ: NVAX) shares jumped on Wednesday after the U.S. Food and Drug Administration (FDA) granted a Fast Track Designation for NanoFlu, its recombinant quadrivalent seasonal influenza vaccine candidate, ...
Read Full Story »